Genine Winslow

Company: Chameleon Biosciences

Job title: Founder & Chief Executive Officer

Bio:

Seasoned rare disease and gene therapy drug developer who brings immunology expertise and AAV based gene therapy translation together to address the immune related challenges facing current AAV based technologies.

Seminars:

Industry Leaders’ Panel: Evaluating Progress of AAV Redosing Developments in 2023 3:30 pm

Outlining the current state of play between ‘one and done’ and ‘low and slow’ approaches? How is the investment landscape of gene therapies impacting developments in redosing? Where are we making significant progress in the field?Read more

day: Pre-Conference Day

Addressing the Barrier of Memory Cell Reactivity 2:00 pm

Outlining the importance of the memory T and B cell response in the formation of anti-AAV antibodies Evaluating the latest immune tolerance approaches to prevent their formation following a priming dose What potential impact does controlling the memory T cell response hold for redosing? Read more

day: Pre-Conference Day